Cargando…

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections

INTRODUCTION: Dalbavancin is approved for acute bacterial skin and skin structure infections (ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive infections. Importantly, dalbavancin’s real benefits may be in treating complicated infections in vulnerable patient p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bork, Jacqueline T., Heil, Emily L., Berry, Shanna, Lopes, Eurides, Davé, Rohini, Gilliam, Bruce L., Amoroso, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522607/ https://www.ncbi.nlm.nih.gov/pubmed/31054088 http://dx.doi.org/10.1007/s40121-019-0247-0

Ejemplares similares

613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy
por: Tuan, Jessica, et al.
Publicado: (2021)

Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
por: Tuan, Jessica J., et al.
Publicado: (2022)

754. Evaluation of Standardized Dalbavancin Use to Facilitate Early Hospital Discharge for Patients Inappropriate for Outpatient Parenteral Antibiotic Therapy
por: Shihadeh, Katherine C, et al.
Publicado: (2019)

968. Effect of Outpatient Antibiotic Ordering Restrictions on Antibiotic Prescribing Patterns at a State-wide VA Healthcare System
por: Dave, Rohini, et al.
Publicado: (2019)

234. Dalbavancin versus Outpatient Parenteral Antimicrobial Therapy with Vancomycin for Treatment of Bone and Joint Infections in a Veteran Population
por: Gibbons, Emily A, et al.
Publicado: (2021)

Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019
por: Bork, Jacqueline T., et al.
Publicado: (2020)

146. Outpatient Antibiotic Stewardship in the COVID Era: Trends in antibiotic prescription in a statewide Veteran’s Affairs health care system
por: Werzen, Alissa, et al.
Publicado: (2020)

Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy
por: Vazquez Deida, Axel A, et al.
Publicado: (2020)

Comparing Injecting Drug Users with Others Receiving Outpatient Parenteral Antibiotic Therapy
por: Dobson, Pauline M, et al.
Publicado: (2017)

Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
por: Smith, Jordan R., et al.
Publicado: (2015)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

Rate of broad-spectrum antibiotic overuse in patients receiving outpatient parenteral antibiotic therapy (OPAT)
por: Brenon, Jessa R., et al.
Publicado: (2021)

An evaluation of risk factors for readmission in patients receiving outpatient parenteral antimicrobial therapy
por: Bradley, Abby C., et al.
Publicado: (2023)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
por: Ajaka, Leama, et al.
Publicado: (2020)

1758. Retrospective cohort analysis of outcomes in patients receiving outpatient parenteral antibiotic therapy (OPAT)
por: Billmeyer, Kaylyn, et al.
Publicado: (2022)

2057. Outpatient Antibiotic Stewardship “Bundles up” in Winter with Peer Comparison, URI Order Set and Education: Is It Enough to Weather the Storm?
por: Akay, Okan I, et al.
Publicado: (2019)

745 Risk of Peripheral Blood Eosinophilia and Hypersensitivity Reactions among Patients Receiving Outpatient Parenteral Antibiotics
por: Blumenthal, Kimberly, et al.
Publicado: (2014)

351. Factors Predicting Readmission within 90 days in Patients Receiving Outpatient Parenteral Antibiotic Therapy
por: Smola, Kyle, et al.
Publicado: (2023)

Managing an outpatient parenteral antibiotic therapy team: challenges and solutions
por: Halilovic, Jenana, et al.
Publicado: (2014)

1298 Predictors of Hospital Readmission in Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Means, Laura, et al.
Publicado: (2014)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin
por: Oliva, Alessandra, et al.
Publicado: (2021)

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series
por: Evins, Connor, et al.
Publicado: (2022)

Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections
por: Rowe, Sarah, et al.
Publicado: (2023)

169 Rapid Testing using Verigene® Microarray in Combination with Antimicrobial Stewardship Intervention in Gram-negative Bacteremia
por: Bork, Jacqueline T., et al.
Publicado: (2014)

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
por: Bryson-Cahn, Chloe, et al.
Publicado: (2019)

688. Risk of Clostridioides difficile Infection and Antibiotic Associated Diarrhea in Patients Receiving Outpatient Parenteral Antimicrobial Therapy
por: Jaramillo, Mario, et al.
Publicado: (2023)

Clinical, contextual and hospital-level factors associated with escalation and de-escalation of empiric Gram-negative antibiotics among US inpatients
por: Baghdadi, Jonathan D, et al.
Publicado: (2023)

Outcomes According to Discharge Location for Persons Who Inject Drugs Receiving Outpatient Parenteral Antimicrobial Therapy
por: D’Couto, Helen T, et al.
Publicado: (2018)

Outpatient parenteral antibiotic therapy (OPAT) for the management of bronchiectasis
por: Tu, Jacky, et al.
Publicado: (2023)

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
por: Poliseno, Mariacristina, et al.
Publicado: (2021)

OPAT: outpatient parenteral antimicrobial therapy
Publicado: (2020)

Outpatient parenteral antimicrobial therapy in Brazil
por: Oliveira, Priscila R, et al.
Publicado: (2023)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context
por: De Nicolò, Amedeo, et al.
Publicado: (2021)

First Pediatric Outpatient Parenteral Antibiotic Therapy Clinic in Indonesia
por: Hendarto, Aryono, et al.
Publicado: (2020)

A little education goes a long way: Decreasing antibiotics for community-acquired pneumonia in COVID-19 patients
por: Tripathi, Ravi, et al.
Publicado: (2022)

753. Outpatient Parenteral Antibiotic Therapy (OPAT) in a Large Urban Safety Net Hospital Setting: Therapy for Vulnerable Populations at Home
por: Ashley Appa, Ayesha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b3ba367q6m6a9ovq5v9u4evv8f